Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 11
Submit an article Journal homepage
256
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak

Milena Kohna Service d’Hématologie, Centre Hospitalier de Versailles, Le Chesnay, France
,
Tamim Alsulimanb Sorbonne Université, INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, FranceORCID Iconhttps://orcid.org/0000-0003-2320-7269
ORCID Icon,
Sylvain Lamurec Department of Clinical Hematology, Montpellier University Hospital, IGMM UMR5535 CNRS, University of Montpellier, Montpellier, France
,
Morgane Cheminantd Service d’Hématologie, Hôpital Necker, Paris, France
,
Jéremy Delagee Service d’Hématologie, Clinique du Parc, France
,
Corinne Merle De Boeverf Département des maladies infectieuses et tropicales, Montpellier University Hospital, Montpellier, France
,
Jean Jacques Tudesqc Department of Clinical Hematology, Montpellier University Hospital, IGMM UMR5535 CNRS, University of Montpellier, Montpellier, France
,
Zora Marjanovicb Sorbonne Université, INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France
,
Zoé Van de Wyngaertb Sorbonne Université, INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France
,
Florent Malardb Sorbonne Université, INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France
,
Eolia Brissotb Sorbonne Université, INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France
,
Sophie Rigaudeaua Service d’Hématologie, Centre Hospitalier de Versailles, Le Chesnay, France
,
Stéphanie Marque-Juilletg Laboratoire de virologie, Centre Hospitalier de Versailles, Le Chesnay, France
,
Audrey Therbyh Service de médecine interne, Centre Hospitalier de Versailles, Le Chesnay, France
,
Guillaume Cartronc Department of Clinical Hematology, Montpellier University Hospital, IGMM UMR5535 CNRS, University of Montpellier, Montpellier, France
,
Philippe Rousselota Service d’Hématologie, Centre Hospitalier de Versailles, Le Chesnay, France
,
Olivier Hermined Service d’Hématologie, Hôpital Necker, Paris, France
,
Rémy Duléryb Sorbonne Université, INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France
&
Caroline Bessona Service d’Hématologie, Centre Hospitalier de Versailles, Le Chesnay, France;i UVSQ, Inserm, Équipe "Exposome et Hérédité", CESP, Université Paris-Saclay, Villejuif, FranceCorrespondence[email protected]
 show all
Pages 2686-2690 | Received 22 Apr 2022, Accepted 29 May 2022, Published online: 18 Jun 2022

References

  • Han S, Zhuang Q, Chiang J, et al. Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and Meta-analysis. BMJ Open. 2022;12(2):e044661.
  • Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168.
  • Duléry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934–944.
  • Chang A, Akhtar A, Linderman SL, et al. Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with Non-Hodgkin lymphoma and chronic lymphocytic leukemia. J Clin Oncol. 2022;107:2411–2502.
  • Kohn M, Delord M, Chbat M, et al. A third anti-SARS-Cov2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia. Haematol. 2021;107(6):1454–1459.
  • O’Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 2021;385(13):1184–1195.
  • Loo Y-M, McTamney PM, Arends RH, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans. Sci Transl Med. 2022;14(635):eabl8124.
  • Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–484.e15.
  • Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The Lancet. 2022;399(10323):437–446.
  • Borah P, Mirgh S, Sharma SK, et al. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells Mol Dis. 2021;87:102525.
  • Bronstein Y, Gat R, Levi S, et al. COVID-19 in patients with lymphoproliferative diseases during the omicron variant surge. Cancer Cell. 2022;2022:15.
  • Passamonti F, Romano A, Salvini M, et al. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br J Haematol. 2021;195(3):371–377.
  • Lamure S, Duléry R, Di Blasi R, et al. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: a retrospective multicentric cohort study. EClinicalMedicine. 2020;27:100549.
  • Visco C, Marcheselli L, Mina R, et al. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. 2022;6(1):327–338.
  • Lewnard JA, Hong VX, Patel MM, et al. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. Epidemiology; 2022. [cited 2022 Feb 17]. Available from: 10.1101/2022.01.11.22269045.
  • de la Cruz-Benito B, Lázaro-Del Campo P, Ramírez-López A, et al. Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. Br J Haematol. 2020;191(3):386–389.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.